In a recent interview, Elizabeth Mitchell, president and CEO of the Purchaser Business Group on Health, discussed employers' ...

After the FDA delayed the approval of MDMA-assisted therapy for PTSD, there's still a way forward for psychedelic medicines, experts said at HLTH.

I frequently have conversations with my patients in their early sixties who are planning for retirement – an important part of which is transitioning from commercial insurance to Medicare.

Most Americans don’t understand how an administration's view on healthcare data sharing interoperability could directly ...

More than two dozen Black and Latino health tech leaders have endorsed Kamala Harris for president. Another group of over 500 ...

Every year, HR and finance leaders play the lottery when it comes to their health insurance costs. Unpredictable renewal rates on their group plans can wreak havoc on a company’s budget, often ...

In 2017, Warren Buffett called the healthcare system “the tapeworm of American economic competitiveness.” Seven years later, this is my staunchly-optimistic counterpoint. First, piles of data ...

Biogen and Sage Therapeutics are discontinuing further development of their drug Zurzuvae as a potential treatment for major depressive disorder, a move that follows last year’s FDA rejection of ...

It’s hard for preclinical biotech companies to go public these days as investors look for human data that can reduce investment risk. Crescent Biopharma is more than a year away from the clinic ...